Clinigen Group Plc (CLINC)

London
610.50
+11.00(+1.83%)
  • Volume:
    910,295
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    597.00 - 620.00

CLINC Overview

Prev. Close
599.5
Day's Range
597-620
Revenue
518.7M
Open
620
52 wk Range
554-891.79
EPS
0.1
Volume
910,295
Market Cap
812.14M
Dividend (Yield)
0.08
(1.25%)
Average Volume (3m)
821,335
P/E Ratio
64.24
Beta
1.47
1-Year Change
-12.73%
Shares Outstanding
133,028,647
Next Earnings Date
15 Sept 2021
What is your sentiment on Clinigen Group Plc?
or
Market is currently closed. Voting is open during market hours.

Clinigen Group Plc News

  • Clinigen crashes by 25% after COVID-19 hits earnings
    • ByProactiveinvestors-

    Shares in Clinigen Group PLC (LON: CLIN) are heading for their worst day on record. The pharmaceutical firm has lost a quarter of its value after it said the fallout from COVID-19...

  • UPDATE 1-UK Stocks-Factors to watch on Sept 17
    • ByReuters-

    Sept 17 (Reuters) - Britain's FTSE 100 (.FTSE) index is seen opening 34 points lower at 6,044 on Thursday, according to financial bookmakers, with futures (FFIc1) seen down 1%...

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralBuySellStrong Sell
Technical IndicatorsStrong SellStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong SellBuyStrong BuyStrong SellStrong Sell

Clinigen Group Plc Company Profile

Clinigen Group Plc Company Profile

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Read More
  • An ideal target for takeover
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.